View Financial HealthHuapont Life SciencesLtd 배당 및 자사주 매입배당 기준 점검 4/6Huapont Life SciencesLtd 은(는) 현재 수익률이 11.21% 인 배당금 지급 회사입니다.핵심 정보11.2%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률5.5%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향130%최근 배당 및 자사주 매입 업데이트공시 • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.공시 • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.공시 • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).공시 • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.공시 • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 5 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026, at 13:30 China Standard Time. Location: No. 69, Xingguang Avenue, Renhe, Yubei District, Chongqing China공시 • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026공시 • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026공시 • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025공시 • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.공시 • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.공시 • Jul 02Huapont Life Sciences Co.,Ltd. to Report First Half, 2025 Results on Aug 20, 2025Huapont Life Sciences Co.,Ltd. announced that they will report first half, 2025 results on Aug 20, 2025공시 • May 16Huapont Life Sciences Co.,Ltd. Approves the Election of Zhang Songshan as Non-Independent DirectorHuapont Life Sciences Co.,Ltd. at its Annual General Meeting held on 14 May 2025 approved the election of Zhang Songshan as non-independent director.공시 • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China공시 • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2025 Results on Apr 23, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025공시 • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.059 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.059 in 3Q 2023). Revenue: CN¥2.99b (flat on 3Q 2023). Net income: CN¥138.5m (up 18% from 3Q 2023). Profit margin: 4.6% (up from 3.9% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥4.75, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 22% over the past three years.공시 • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Reported Earnings • Aug 31Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.11 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.08 (down from CN¥0.11 in 2Q 2023). Revenue: CN¥3.01b (up 3.9% from 2Q 2023). Net income: CN¥158.0m (down 25% from 2Q 2023). Profit margin: 5.3% (down from 7.3% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.공시 • Jun 29Huapont Life Sciences Co.,Ltd to Report First Half, 2024 Results on Aug 31, 2024Huapont Life Sciences Co.,Ltd announced that they will report first half, 2024 results on Aug 31, 2024Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.공시 • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).공시 • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.공시 • Apr 29Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing ChinaReported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.09 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.079 (down from CN¥0.09 in 1Q 2023). Revenue: CN¥2.92b (down 2.0% from 1Q 2023). Net income: CN¥155.6m (down 12% from 1Q 2023). Profit margin: 5.3% (down from 6.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.공시 • Mar 30Huapont Life Sciences Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report Q1, 2024 results on Apr 27, 2024Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥4.50, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 25x in the Chemicals industry in China. Total returns to shareholders of 2.4% over the past three years.공시 • Dec 29+ 1 more updateHuapont Life Sciences Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report fiscal year 2023 results on Apr 27, 2024Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Dec 13+ 1 more updateHuapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component IndexHuapont-Nutrichem Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index.Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.079 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.059 (down from CN¥0.079 in 3Q 2022). Revenue: CN¥2.98b (down 14% from 3Q 2022). Net income: CN¥117.8m (down 25% from 3Q 2022). Profit margin: 3.9% (down from 4.5% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.20 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.20 in 2Q 2022). Revenue: CN¥2.89b (down 12% from 2Q 2022). Net income: CN¥210.0m (down 46% from 2Q 2022). Profit margin: 7.3% (down from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.공시 • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.공시 • May 19Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022Huapont Life Sciences Co.,Ltd approved final cash dividend per 10 shares (tax included) of CNY 2.20000000 for the year 2022 at its Annual General Meeting of 2022 on 17 May 2023.Reported Earnings • Apr 28First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.085 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.09 (up from CN¥0.085 in 1Q 2022). Revenue: CN¥2.98b (down 13% from 1Q 2022). Net income: CN¥177.1m (up 5.0% from 1Q 2022). Profit margin: 6.0% (up from 5.0% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.Buying Opportunity • Apr 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be CN¥6.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last year. Earnings per share has grown by 32%.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.08 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.079 (down from CN¥0.08 in 3Q 2021). Revenue: CN¥3.48b (up 21% from 3Q 2021). Net income: CN¥157.1m (down 6.2% from 3Q 2021). Profit margin: 4.5% (down from 5.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.20 (up from CN¥0.12 in 2Q 2021). Revenue: CN¥3.30b (up 13% from 2Q 2021). Net income: CN¥391.3m (up 69% from 2Q 2021). Profit margin: 12% (up from 7.9% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.06 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.085 (up from CN¥0.06 in 1Q 2021). Revenue: CN¥3.40b (up 21% from 1Q 2021). Net income: CN¥168.6m (up 39% from 1Q 2021). Profit margin: 5.0% (up from 4.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥0.34 (up from CN¥0.33 in FY 2020). Revenue: CN¥12.4b (up 14% from FY 2020). Net income: CN¥670.0m (up 2.8% from FY 2020). Profit margin: 5.4% (down from 6.0% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥7.40, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 65% over the past three years.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.10 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥2.88b (up 6.4% from 3Q 2020). Net income: CN¥167.5m (down 15% from 3Q 2020). Profit margin: 5.8% (down from 7.3% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 68% over the past three years.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 26% share price gain to CN¥7.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 72% over the past three years.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: CN¥2.93b (flat on 2Q 2020). Net income: CN¥231.5m (down 1.3% from 2Q 2020). Profit margin: 7.9% (down from 8.0% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.82b (up 25% from 1Q 2020). Net income: CN¥121.6m (up 47% from 1Q 2020). Profit margin: 4.3% (up from 3.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 7.8% from FY 2019). Net income: CN¥651.7m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 04Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 8.4% from FY 2019). Net income: CN¥652.1m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Jan 25New 90-day low: CN¥5.02The company is down 3.0% from its price of CN¥5.19 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.Is New 90 Day High Low • Dec 14New 90-day high: CN¥6.06The company is up 14% from its price of CN¥5.32 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 18New 90-day high: CN¥5.71The company is up 2.0% from its price of CN¥5.62 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 5.0% over the same period.Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥627.2m, up 19% from the prior year. Total revenue was CN¥10.5b over the last 12 months, up 2.7% from the prior year.Is New 90 Day High Low • Sep 24New 90-day low: CN¥5.18The company is down 2.0% from its price of CN¥5.26 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 002004 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: 002004 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Huapont Life SciencesLtd 배당 수익률 vs 시장002004의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (002004)11.2%시장 하위 25% (CN)0.4%시장 상위 25% (CN)2.1%업계 평균 (Chemicals)1.3%분석가 예측 (002004) (최대 3년)n/a주목할만한 배당금: 002004 의 배당금( 11.21% )은 CN 시장에서 배당금 지급자의 하위 25%( 0.38% )보다 높습니다.고배당: 002004 의 배당금( 11.21% )은 CN 시장( 2.14% )주주 대상 이익 배당수익 보장: 지급 비율 ( 129.8% )이 높기 때문에 002004 의 배당금 지급은 수익으로 잘 충당되지 않습니다.주주 현금 배당현금 흐름 범위: 합리적인 현금 지급 비율 ( 58.1% )로 002004 의 배당금 지급은 현금 흐름으로 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 08:12종가2026/06/09 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Huapont Life Sciences Co.,Ltd.는 7명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bing GaoChina International Capital Corporation LimitedSissie OuChina Stock Investment Research Co. Ltd. (GZ500..com)Wei MaoEverbright Securities Co. Ltd.4명의 분석가 더 보기
공시 • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.
공시 • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.
Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.
공시 • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).
공시 • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.
공시 • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 5 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026, at 13:30 China Standard Time. Location: No. 69, Xingguang Avenue, Renhe, Yubei District, Chongqing China
공시 • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026
공시 • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
공시 • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.
공시 • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.
공시 • Jul 02Huapont Life Sciences Co.,Ltd. to Report First Half, 2025 Results on Aug 20, 2025Huapont Life Sciences Co.,Ltd. announced that they will report first half, 2025 results on Aug 20, 2025
공시 • May 16Huapont Life Sciences Co.,Ltd. Approves the Election of Zhang Songshan as Non-Independent DirectorHuapont Life Sciences Co.,Ltd. at its Annual General Meeting held on 14 May 2025 approved the election of Zhang Songshan as non-independent director.
공시 • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China
공시 • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2025 Results on Apr 23, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025
공시 • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.059 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.059 in 3Q 2023). Revenue: CN¥2.99b (flat on 3Q 2023). Net income: CN¥138.5m (up 18% from 3Q 2023). Profit margin: 4.6% (up from 3.9% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥4.75, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 22% over the past three years.
공시 • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Reported Earnings • Aug 31Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.11 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.08 (down from CN¥0.11 in 2Q 2023). Revenue: CN¥3.01b (up 3.9% from 2Q 2023). Net income: CN¥158.0m (down 25% from 2Q 2023). Profit margin: 5.3% (down from 7.3% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
공시 • Jun 29Huapont Life Sciences Co.,Ltd to Report First Half, 2024 Results on Aug 31, 2024Huapont Life Sciences Co.,Ltd announced that they will report first half, 2024 results on Aug 31, 2024
Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.
공시 • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).
공시 • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.
공시 • Apr 29Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China
Reported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.09 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.079 (down from CN¥0.09 in 1Q 2023). Revenue: CN¥2.92b (down 2.0% from 1Q 2023). Net income: CN¥155.6m (down 12% from 1Q 2023). Profit margin: 5.3% (down from 6.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
공시 • Mar 30Huapont Life Sciences Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report Q1, 2024 results on Apr 27, 2024
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥4.50, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 25x in the Chemicals industry in China. Total returns to shareholders of 2.4% over the past three years.
공시 • Dec 29+ 1 more updateHuapont Life Sciences Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report fiscal year 2023 results on Apr 27, 2024
Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Dec 13+ 1 more updateHuapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component IndexHuapont-Nutrichem Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index.
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.079 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.059 (down from CN¥0.079 in 3Q 2022). Revenue: CN¥2.98b (down 14% from 3Q 2022). Net income: CN¥117.8m (down 25% from 3Q 2022). Profit margin: 3.9% (down from 4.5% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.20 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.20 in 2Q 2022). Revenue: CN¥2.89b (down 12% from 2Q 2022). Net income: CN¥210.0m (down 46% from 2Q 2022). Profit margin: 7.3% (down from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
공시 • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.
공시 • May 19Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022Huapont Life Sciences Co.,Ltd approved final cash dividend per 10 shares (tax included) of CNY 2.20000000 for the year 2022 at its Annual General Meeting of 2022 on 17 May 2023.
Reported Earnings • Apr 28First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.085 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.09 (up from CN¥0.085 in 1Q 2022). Revenue: CN¥2.98b (down 13% from 1Q 2022). Net income: CN¥177.1m (up 5.0% from 1Q 2022). Profit margin: 6.0% (up from 5.0% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.
Buying Opportunity • Apr 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be CN¥6.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last year. Earnings per share has grown by 32%.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.08 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.079 (down from CN¥0.08 in 3Q 2021). Revenue: CN¥3.48b (up 21% from 3Q 2021). Net income: CN¥157.1m (down 6.2% from 3Q 2021). Profit margin: 4.5% (down from 5.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.20 (up from CN¥0.12 in 2Q 2021). Revenue: CN¥3.30b (up 13% from 2Q 2021). Net income: CN¥391.3m (up 69% from 2Q 2021). Profit margin: 12% (up from 7.9% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.
Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.06 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.085 (up from CN¥0.06 in 1Q 2021). Revenue: CN¥3.40b (up 21% from 1Q 2021). Net income: CN¥168.6m (up 39% from 1Q 2021). Profit margin: 5.0% (up from 4.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥0.34 (up from CN¥0.33 in FY 2020). Revenue: CN¥12.4b (up 14% from FY 2020). Net income: CN¥670.0m (up 2.8% from FY 2020). Profit margin: 5.4% (down from 6.0% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥7.40, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 65% over the past three years.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.10 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥2.88b (up 6.4% from 3Q 2020). Net income: CN¥167.5m (down 15% from 3Q 2020). Profit margin: 5.8% (down from 7.3% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 68% over the past three years.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 26% share price gain to CN¥7.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 72% over the past three years.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: CN¥2.93b (flat on 2Q 2020). Net income: CN¥231.5m (down 1.3% from 2Q 2020). Profit margin: 7.9% (down from 8.0% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.82b (up 25% from 1Q 2020). Net income: CN¥121.6m (up 47% from 1Q 2020). Profit margin: 4.3% (up from 3.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 7.8% from FY 2019). Net income: CN¥651.7m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 04Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 8.4% from FY 2019). Net income: CN¥652.1m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Jan 25New 90-day low: CN¥5.02The company is down 3.0% from its price of CN¥5.19 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.
Is New 90 Day High Low • Dec 14New 90-day high: CN¥6.06The company is up 14% from its price of CN¥5.32 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 18New 90-day high: CN¥5.71The company is up 2.0% from its price of CN¥5.62 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 5.0% over the same period.
Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥627.2m, up 19% from the prior year. Total revenue was CN¥10.5b over the last 12 months, up 2.7% from the prior year.
Is New 90 Day High Low • Sep 24New 90-day low: CN¥5.18The company is down 2.0% from its price of CN¥5.26 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.